JP2009519311A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009519311A5 JP2009519311A5 JP2008545090A JP2008545090A JP2009519311A5 JP 2009519311 A5 JP2009519311 A5 JP 2009519311A5 JP 2008545090 A JP2008545090 A JP 2008545090A JP 2008545090 A JP2008545090 A JP 2008545090A JP 2009519311 A5 JP2009519311 A5 JP 2009519311A5
- Authority
- JP
- Japan
- Prior art keywords
- reverse transcriptase
- transcriptase inhibitor
- functional derivative
- tablet
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 14
- 229940123527 Nucleotide reverse transcriptase inhibitor Drugs 0.000 claims 13
- 239000000825 pharmaceutical preparation Substances 0.000 claims 13
- 239000003826 tablet Substances 0.000 claims 13
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 12
- 239000002552 dosage form Substances 0.000 claims 11
- 239000010410 layer Substances 0.000 claims 9
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 5
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims 5
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims 3
- 229960003804 efavirenz Drugs 0.000 claims 3
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims 3
- 229960001627 lamivudine Drugs 0.000 claims 3
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229940127557 pharmaceutical product Drugs 0.000 claims 3
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical group OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 3
- 239000011247 coating layer Substances 0.000 claims 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 claims 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims 1
- 229960004748 abacavir Drugs 0.000 claims 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims 1
- 229960001997 adefovir Drugs 0.000 claims 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 229960005319 delavirdine Drugs 0.000 claims 1
- -1 emitricitabine Chemical compound 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000007942 layered tablet Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960000689 nevirapine Drugs 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960001203 stavudine Drugs 0.000 claims 1
- 229960002555 zidovudine Drugs 0.000 claims 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1566MU2005 | 2005-12-14 | ||
| IN1566/MUM/2005 | 2005-12-14 | ||
| IN1878MU2006 | 2006-11-13 | ||
| IN1878/MUM/2006 | 2006-11-13 | ||
| PCT/GB2006/004687 WO2007068934A2 (en) | 2005-12-14 | 2006-12-14 | Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009519311A JP2009519311A (ja) | 2009-05-14 |
| JP2009519311A5 true JP2009519311A5 (enExample) | 2010-02-04 |
| JP5231242B2 JP5231242B2 (ja) | 2013-07-10 |
Family
ID=38163276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008545090A Active JP5231242B2 (ja) | 2005-12-14 | 2006-12-14 | ヌクレオチド及びヌクレオシド系逆転写酵素阻害剤（テノホビル及びラミブジン）を剤形の異なる部分に含む医薬組合せ |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20080317852A1 (enExample) |
| EP (1) | EP2051703B1 (enExample) |
| JP (1) | JP5231242B2 (enExample) |
| KR (1) | KR20080091767A (enExample) |
| AP (1) | AP2008004533A0 (enExample) |
| AT (1) | ATE474560T1 (enExample) |
| AU (1) | AU2006325404B2 (enExample) |
| BR (1) | BRPI0620705A2 (enExample) |
| CA (1) | CA2633603C (enExample) |
| DE (1) | DE602006015721D1 (enExample) |
| MA (1) | MA30161B1 (enExample) |
| NZ (1) | NZ569349A (enExample) |
| RU (1) | RU2008128424A (enExample) |
| SI (1) | SI2051703T1 (enExample) |
| WO (1) | WO2007068934A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040224917A1 (en) | 2003-01-14 | 2004-11-11 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| WO2009037449A1 (en) * | 2007-09-18 | 2009-03-26 | Cipla Limited | Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors |
| PA8809601A1 (es) | 2007-12-24 | 2009-07-23 | Cipla Ltd | Combinación anti-retroviral |
| WO2009106954A1 (en) * | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Stable dosage forms of lamivudine and tenofovir |
| WO2009106960A2 (en) * | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Stable compositions of lamivudine, tenofovir and efavirenz |
| HRP20151357T1 (hr) | 2008-05-02 | 2016-01-29 | Gilead Sciences, Inc. | Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa |
| EA021313B1 (ru) * | 2009-02-06 | 2015-05-29 | Джилид Сайэнс, Инк. | Таблетки для комбинированной терапии |
| WO2010125572A1 (en) * | 2009-04-29 | 2010-11-04 | Hetero Research Foundation | Compressed tablets and capsules containing efavirenz |
| EP2435052B1 (en) | 2009-05-27 | 2015-07-15 | Hetero Research Foundation | Solid oral dosage forms of lamivudine with isomalt |
| EP2389929A1 (en) * | 2010-05-30 | 2011-11-30 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Pharmaceutical formulations of tenofovir |
| EP2579892A2 (en) | 2010-06-09 | 2013-04-17 | Vaccine Technologies, Incorporated | Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment |
| ES2524408T5 (es) | 2010-11-19 | 2022-04-25 | Gilead Sciences Inc | Composiciones terapéuticas que comprenden rilpivirina HCl y tenofovir disoproxil fumarato |
| US20140193491A1 (en) * | 2011-05-30 | 2014-07-10 | Cipla Limited | Pharmaceutical antiretroviral composition |
| CN103211826A (zh) * | 2013-05-14 | 2013-07-24 | 福建广生堂药业股份有限公司 | 一种抗病毒药物组合物及其制备方法和用途 |
| WO2015014737A1 (en) * | 2013-07-29 | 2015-02-05 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Multilayer tablet formulations comprising tenofovir and entecavir |
| AU2015290400B2 (en) * | 2014-07-18 | 2017-12-07 | Jw Pharmaceutical Corporation | Novel salt of tenofovir disoproxil |
| CN104473896B (zh) * | 2014-12-01 | 2017-04-19 | 东莞市金美济药业有限公司 | 一种快速崩解的拉米夫定片及其制备工艺 |
| HUE056978T2 (hu) * | 2015-12-02 | 2022-04-28 | Merck Sharp & Dohme | Doravirint, tenofovir-dizoproxil-fumarátot és lamivudint tartalmazó gyógyszerészeti kompozíciók |
| TR201617448A2 (tr) | 2016-11-29 | 2018-06-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler |
| CN106822155B (zh) * | 2016-12-29 | 2019-10-11 | 东北制药集团股份有限公司 | 依非韦伦、拉米夫定及富马酸替诺福韦酯三联复方片中片及其制备方法 |
| RU2644156C1 (ru) | 2017-02-28 | 2018-02-08 | Александр Васильевич Иващенко | Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения |
| RU2662160C9 (ru) * | 2017-07-03 | 2018-10-22 | Александрович Иващенко Андрей | Комбинированный лекарственный препарат для терапии вирусных инфекций |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL108838C (enExample) * | 1956-03-27 | |||
| CS263951B1 (en) * | 1985-04-25 | 1989-05-12 | Antonin Holy | 9-(phosponylmethoxyalkyl)adenines and method of their preparation |
| US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| US5366972A (en) * | 1989-04-20 | 1994-11-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection |
| US6057305A (en) * | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
| US5663169A (en) * | 1992-08-07 | 1997-09-02 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
| IT1264696B1 (it) * | 1993-07-09 | 1996-10-04 | Applied Pharma Res | Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata |
| US5922695A (en) * | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5733788A (en) * | 1996-07-26 | 1998-03-31 | Gilead Sciences, Inc. | PMPA preparation |
| US5935946A (en) * | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| UA72207C2 (uk) * | 1998-04-07 | 2005-02-15 | Брістол- Майєрс Сквібб Фарма Компані | Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення |
| GB9820420D0 (en) * | 1998-09-18 | 1998-11-11 | Glaxo Group Ltd | Antiviral combinations |
| ZA200110499B (en) * | 2001-05-11 | 2002-04-03 | Cipla Medpro Pty Ltd | Pharmaceutical composition. |
| ZA200110501B (en) * | 2001-05-11 | 2002-04-03 | Cipla Medpro Pty Ltd | Pharmaceutical composition. |
| MY169670A (en) * | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| US20050175694A1 (en) * | 2002-04-23 | 2005-08-11 | Himadri Sen | Long acting compositions comprising zidovudine and lamivudine |
| TWI332956B (en) * | 2002-04-26 | 2010-11-11 | Gilead Sciences Inc | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds |
| WO2004043433A2 (en) * | 2002-11-08 | 2004-05-27 | Glaxo Group Limited | Pharmaceutical antiviral compositions |
| US20040224917A1 (en) * | 2003-01-14 | 2004-11-11 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
| US20050048112A1 (en) * | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
| TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| US20070059360A1 (en) * | 2005-07-29 | 2007-03-15 | Ashish Jaiswal | Water-dispersible anti-retroviral pharmaceutical compositions |
-
2006
- 2006-12-14 RU RU2008128424/15A patent/RU2008128424A/ru not_active Application Discontinuation
- 2006-12-14 NZ NZ569349A patent/NZ569349A/en unknown
- 2006-12-14 AT AT06820527T patent/ATE474560T1/de not_active IP Right Cessation
- 2006-12-14 WO PCT/GB2006/004687 patent/WO2007068934A2/en not_active Ceased
- 2006-12-14 SI SI200630809T patent/SI2051703T1/sl unknown
- 2006-12-14 US US12/097,387 patent/US20080317852A1/en not_active Abandoned
- 2006-12-14 BR BRPI0620705-7A patent/BRPI0620705A2/pt not_active IP Right Cessation
- 2006-12-14 DE DE602006015721T patent/DE602006015721D1/de active Active
- 2006-12-14 EP EP06820527A patent/EP2051703B1/en not_active Not-in-force
- 2006-12-14 JP JP2008545090A patent/JP5231242B2/ja active Active
- 2006-12-14 CA CA2633603A patent/CA2633603C/en not_active Expired - Fee Related
- 2006-12-14 AP AP2008004533A patent/AP2008004533A0/xx unknown
- 2006-12-14 AU AU2006325404A patent/AU2006325404B2/en not_active Ceased
- 2006-12-14 KR KR1020087016727A patent/KR20080091767A/ko not_active Ceased
-
2008
- 2008-07-11 MA MA31114A patent/MA30161B1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009519311A5 (enExample) | ||
| RU2008128424A (ru) | Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы | |
| CN101352426B (zh) | 一种渗透泵控释制剂组合物及其制备方法 | |
| ES2374117T3 (es) | Componente de silibinina para el tratamiento de la hepatitis. | |
| JP2004506009A5 (enExample) | ||
| UA72783C2 (en) | Agonist of central canabinoid receptors for preparation of drug disaccustoming smoking, combined pharmaceutical composition and kit | |
| WO2013132208A1 (en) | Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine | |
| BRPI0513909A (pt) | comprimido farmacêutico de camada múltipla para a liberação controlada de ingredientes ativos com solubilidade altamente dependente do ph | |
| JP2013544290A5 (enExample) | ||
| Strauch et al. | COMMENTARY: Biowaiver monographs for immediate release solid oral dosage forms: Lamivudine | |
| Nelson et al. | Emtricitabine (FTC) for the treatment of HIV infection | |
| Hurwitz et al. | Practical considerations for developing nucleoside reverse transcriptase inhibitors | |
| MX2010007281A (es) | Composiciones farmaceuticas de amlodipina y valsartan. | |
| EP2714045A1 (en) | Pharmaceutical antiretroviral composition | |
| WO2013057469A1 (en) | Pharmaceutical antiretroviral compositions | |
| WO2009037449A1 (en) | Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors | |
| Muñoz de Benito et al. | Tenofovir disoproxil fumarate–emtricitabine coformulation for once-daily dual NRTI backbone | |
| WO2018028841A1 (en) | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz | |
| US20080038344A1 (en) | Solid Pharmaceutical Preparation | |
| EP3496719A1 (en) | A multi-class anti-retroviral composition | |
| CN117500494A (zh) | 有利的抗hcv联合疗法 | |
| JP2005500252A (ja) | リバビリン又はマイコフェノール酸などのｉｍｄｐｈ阻害剤とｄａｐｄの併用療法 | |
| EP3334419A1 (en) | Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz | |
| CA2651232C (en) | Combination of alovudine and zidovudine in a molar ratio of 1:100 to 1:350 | |
| WO2006001029A2 (en) | Antiretroviral compositions |